Home | Client Services | Personalized Molecular Diagnostics™ | FLT3 Clinical Trials | Contact

Currently there are several clinical trials for acute myeloid leukemia that include tyrosine kinase inhibitors (TKIs) that target FLT3. TKIs act to reduce the activity of FLT3 and other tyrosine kinase enzymes known to be important to the cancer process. Many of these trials require that the patient have a known FLT3 variation such as the Internal Tandem Duplication or the D835 variation.

Below are summaries of and links to the clinical trials which include TKIs targeting FLT3. The clinical trials listed are currently accepting new patients or soon will be.

Trial Name: Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia ClinicalTrials.gov Identifier: NCT00469859 Trial Phase I & II Tyrosine Kinase Inhibitor, Manufacturer Lestaurtinib (CEP-701), Cephalon Principal Investigator/s; Institution/s: Patrick A. Brown, MD; Sidney Kimmel Comprehensive Cancer Center Donald Small, MD, PhD; Sidney Kimmel Comprehensive Cancer Center FLT3 Variation Required for Study Enrollment? Yes

Trial Name: Study of CEP-701 in Patients With Acute Myeloid Leukemia (AML) ClinicalTrials.gov Identifier: NCT00079482 Trial Phase II Tyrosine Kinase Inhibitor, Manufacturer Lestaurtinib (CEP-701), Cephalon Principal Investigator/s; Institution/s: Cephalon FLT3 Variation Required for Study Enrollment? Yes

Trial Name: Danorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia ClinicalTrials.gov Identifier: NCT00651261 Trial Phase III Tyrosine Kinase Inhibitor, Manufacturer Midostaurin (PKC412), Novartis Principal Investigator/s; Institution/s: Richard M. Stone, MD; Dana-Farber Cancer Institute FLT3 Variation Required for Study Enrollment? Yes

Trial Name: Sorafenib and Cytarabine in Treating Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome ClinicalTrials.gov Identifier: NCT00516828 Trial Phase I & II Tyrosine Kinase Inhibitor, Manufacturer Sorafenib (BAY 43-9006), Bayer Principal Investigator/s; Institution/s: Brian Leber, MD, FRCPC, McMaster Children's Hospital David A. MacDonald, MD, Nova Scotia Cancer Centre FLT3 Variation Required for Study Enrollment? No

Trial Name: Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) ClinicalTrials.gov Identifier: NCT00542971 Trial Phase I & II Tyrosine Kinase Inhibitor, Manufacturer Sorafenib (BAY 43-9006), Bayer Principal Investigator/s; Institution/s: Farhad Ravandi Kashani, MD, M.D. Anderson Cancer Center FLT3 Variation Required for Study Enrollment? No

Trial Name: Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia ClinicalTrials.gov Identifier: NCT00217646 Trial Phase I Tyrosine Kinase Inhibitor, Manufacturer Sorafenib (BAY 43-9006), Bayer Principal Investigator/s; Institution/s: Jorge Cortes, MD, M.D. Anderson Cancer Center FLT3 Variation Required for Study Enrollment? No

Trial Name: Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML ClinicalTrials.gov Identifier: NCT00373373 Trial Phase II Tyrosine Kinase Inhibitor, Manufacturer Sorafenib (BAY 43-9006), Bayer Principal Investigator/s; Institution/s: Hubert Serve, MD; Klinikum der J.W. Goethe Universität Frankfurt FLT3 Variation Required for Study Enrollment? No

Trial Name: A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status ClinicalTrials.gov Identifier: NCT00462761 Trial Phase I Tyrosine Kinase Inhibitor, Manufacturer AC220, Ambit Biosciences Principal Investigator/s; Institution/s: Ambit Clinical Research & Development FLT3 Variation Required for Study Enrollment? No